» Articles » PMID: 24821383

Investigating the Impact of Nanoparticle Size on Active and Passive Tumor Targeting Efficiency

Overview
Journal ACS Nano
Specialty Biotechnology
Date 2014 May 14
PMID 24821383
Citations 201
Authors
Affiliations
Soon will be listed here.
Abstract

Understanding the principles governing the design of nanoparticles for tumor targeting is essential for the effective diagnosis and treatment of solid tumors. There is currently a poor understanding of how to rationally engineer nanoparticles for tumor targeting. Here, we engineered different-sized spherical gold nanoparticles to discern the effect of particle diameter on passive (poly(ethylene glycol)-coated) and active (transferrin-coated) targeting of MDA-MB-435 orthotopic tumor xenografts. Tumor accumulation of actively targeted nanoparticles was found to be 5 times faster and approximately 2-fold higher relative to their passive counterparts within the 60 nm diameter range. For 15, 30, and 100 nm, we observed no significant differences. We hypothesize that such enhancements are the result of an increased capacity to penetrate into tumors and preferentially associate with cancer cells. We also use computational modeling to explore the mechanistic parameters that can impact tumor accumulation efficacy. We demonstrate that tumor accumulation can be mediated by high nanoparticle avidity and are weakly dependent on their plasma clearance rate. Such findings suggest that empirical models can be used to rapidly screen novel nanomaterials for relative differences in tumor targeting without the need for animal work. Although our findings are specific to MDA-MB-435 tumor xenografts, our experimental and computational findings help to enrich knowledge of design considerations that will aid in the optimal engineering of spherical gold nanoparticles for cancer applications in the future.

Citing Articles

Nanomedicine Innovations for Lung Cancer Diagnosis and Therapy.

Cardoso V, Bistaffa M, Sterman R, Lima L, Toldo G, Cancino-Bernardi J ACS Appl Mater Interfaces. 2025; 17(9):13197-13220.

PMID: 40045524 PMC: 11891907. DOI: 10.1021/acsami.4c16840.


Biodistribution of Zr-Radiolabeled Nanoassemblies for Monoclonal Antibody Delivery Revealed through PET Imaging.

Lopez-Estevez A, Carrascal-Minino A, Torres D, Alonso M, T M de Rosales R, Pellico J ACS Omega. 2025; 10(5):4763-4773.

PMID: 39959112 PMC: 11822718. DOI: 10.1021/acsomega.4c09823.


Strategies for specific multimodal imaging of cancer-associated fibroblasts and applications in theranostics of cancer.

Wen L, He C, Guo Y, Zhou N, Meng X, Chen Y Mater Today Bio. 2025; 30():101420.

PMID: 39839493 PMC: 11745968. DOI: 10.1016/j.mtbio.2024.101420.


The Effect of the Size of Gold Nanoparticle Contrast Agents on CT Imaging of the Gastrointestinal Tract and Inflammatory Bowel Disease.

Rosario-Berrios D, Pang A, Liu L, Maidment P, Kim J, Yoon S Bioconjug Chem. 2025; 36(2):233-244.

PMID: 39786354 PMC: 11839313. DOI: 10.1021/acs.bioconjchem.4c00507.


Targeting superficial cancers with gold nanoparticles: a review of current research.

Gomes S, Gaspar M, Coelho J, Reis C Ther Deliv. 2024; 15(10):781-799.

PMID: 39314189 PMC: 11457633. DOI: 10.1080/20415990.2024.2395249.